HIV epitope-specific T-cell receptor (HIV-TCR)

The HIV epitope-specific T-cell receptor (TCR) is a specialized heterodimeric protein complex expressed on the surface of CD8+ T cells that mediates the recognition of cells infected with the Human Immunodeficiency Virus (Varela-Rohena et al., 2008). These receptors specifically bind to viral peptides, such as those derived from the Gag, Pol, or Env proteins, when they are presented by Major Histocompatibility Complex (MHC) class I molecules (Hale et al., 2017). Upon binding, the TCR initiates a signaling cascade that leads to the release of cytotoxic granules, such as perforin and granzymes, which induce apoptosis in the infected cell (Kitchen et al., 2012). In therapeutic development, high-affinity TCRs are engineered into patient-derived T cells (TCR-T therapy) or incorporated into bispecific molecules like Immune mobilizing monoclonal TCRs Against Virus (ImmTAV) to enhance the immune system's ability to clear the viral reservoir (Immunocore, 2023). However, the effectiveness of these strategies is often challenged by HIV's high mutation rate, which allows for the emergence of escape mutants that the TCR can no longer recognize (Varela-Rohena et al., 2008). Furthermore, safety remains a critical concern, as engineered TCRs must be rigorously screened to avoid off-target reactivity against similar human self-antigens, which could lead to severe autoimmunity (Hale et al., 2017).

Other names

HIV-specific T-cell receptorHuman immunodeficiency virus-specific TCRAnti-HIV TCRHIV peptide-specific T-cell receptor

Recognition of HIV-specific peptides presented by MHC Class I molecules on infected cells, triggering T-cell activation, cytokine production, and cytotoxic killing of the target cell.